Bicara Therapeutics (BCAX) Accounts Payables (2023 - 2026)

Bicara Therapeutics has reported Accounts Payables for 4 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 57.14% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 57.14% YoY), and the FY2025 full-year result was $1.1 million, up 83.33% from the prior year.
• Accounts Payables for Q1 2026 stood at $1.1 million, roughly flat from $1.1 million in the prior quarter.
• The five-year high for Accounts Payables was $1.9 million in Q3 2025, with the low at $600000.0 in Q4 2024.
• Historically, Accounts Payables has averaged $1.1 million across 4 years, with a median of $1.1 million in 2025.
• Annual changes were most pronounced in 2024 — Accounts Payables plunged 40.0% — and 2025, when it soared 83.33%.
• Bicara Therapeutics' Accounts Payables stood at $1.0 million in 2023, then sank by 40.0% to $600000.0 in 2024, then surged by 83.33% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
• The last three Accounts Payables figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.